rosiglitazone has been researched along with Body Weight in 177 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (2.82) | 18.2507 |
| 2000's | 100 (56.50) | 29.6817 |
| 2010's | 69 (38.98) | 24.3611 |
| 2020's | 3 (1.69) | 2.80 |
| Authors | Studies |
|---|---|
| Almaden, JV; Bailey, S; Barnum, SJ; Carlson, TJ; Christie, LC; Do, QQ; Fraser, JD; Hess, M; Humphries, PS; Kellum, J; Kim, YH; McClellan, GA; Ogilvie, KM; Simmons, BH; Skalitzky, D; Sun, S; Wilhite, D; Zehnder, LR | 1 |
| Almaden, JV; Barnum, SJ; Carlson, TJ; Do, QQ; Fraser, JD; Hess, M; Humphries, PS; Kim, YH; Ogilvie, KM; Sun, S | 1 |
| Chen, ML; Leng, Y; Shen, JH; Shen, Y; Tang, J; Xu, TF; Ye, YL; Yin, HZ; Zhou, Z; Zou, HJ | 1 |
| Hiramoto, M; Hirao, A; Irii, H; Ishii, H; Okamoto, M; Shibata, S; Shimizu, I; Tahara, Y; Takanishi, A; Udagawa, H; Yasuda, K | 1 |
| Altieri, F; Azzariti, A; Cervoni, L; Crestani, M; Di Giovanni, C; Fracchiolla, G; Gilardi, F; Giudici, M; Guerrini, U; Laghezza, A; Lavecchia, A; Loiodice, F; Mitro, N; Montanari, R; Paradiso, A; Piemontese, L; Pochetti, G; Porcelli, L; Simone, GM; Tortorella, P | 1 |
| Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C | 1 |
| Bao, L; Chen, B; Han, J; Liu, H; Luo, H; Ma, K; Ren, J; Wang, K; Zhang, J | 1 |
| Berthelot, P; Beucher-Gaudin, M; Caignard, DH; Dacquet, C; Farce, A; Géant, A; Hennuyer, N; Ktorza, A; Lebegue, N; Leclerc, V; Pirat, C; Staels, B; Zanirato, G | 1 |
| Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N | 1 |
| Chen, A; Jin, R; Lu, J; Ren, Y; Xuan, F; Ye, Y; Zhou, W | 1 |
| Blazina, I; Selph, S | 1 |
| Fan, R; Li, J; Pei, W; Wang, H; Wang, X; Wang, Y; Zeng, X; Zhang, Y | 1 |
| Hu, A; Hu, Y; Li, D; Li, H; Ying, H | 1 |
| den Hartigh, LJ; Goodspeed, L; Houston, B; Turk, KE; Wang, S | 1 |
| Area-Gomez, E; Chan, M; Creusot, RJ; Fan, L; Fu, W; Ji, R; Kon, N; Kraakman, MJ; Larrea, D; Liu, Q; Namwanje, M; Postigo-Fernandez, J; Qiang, L | 1 |
| Chai, BK; Dharmani, DM; Lau, YS; Loong, BJ; Mohankumar, SK; Rais, MM; Ting, KN | 1 |
| Arteel, GE; Chartoumpekis, DV; Fazzari, M; Freeman, BA; Guimaraes, DA; Khoo, NKH; Li, L; Shiva, S | 1 |
| Hoo, RL; Xu, A; Ye, H; Zhang, HJ | 1 |
| Patel, SS; Udayabanu, M | 1 |
| Chen, SZ; Xiao, JD | 1 |
| Cha, BS; Huh, JH; Kang, ES; Kang, SB; Kim, HJ; Kim, HM; Lee, BW; Lee, HC; Seok, H | 1 |
| Barua, CC; Bezbaruah, B; Gaikwad, AB; Kumar, P; Prashanth, KS; Vij, M | 1 |
| Ezhumalai, M; Pugalendi, KV; Radhiga, T | 1 |
| Chang, Y; Hu, S; Li, Z; Wang, J; Wang, Y; Xue, C | 1 |
| Bland, JS; Darland, G; Desai, A; Grayson, N; Konda, VR | 1 |
| Sun, XD; Yu, YR | 1 |
| Abou Daya, K; Abu Daya, H; Nahhas, G; Nasser Eddine, M; Nuwayri-Salti, N | 1 |
| Chaudhary, T; Kumar, A; Mishra, J | 1 |
| Hao, M; Hu, YR; Kuang, HY; Xiao, YC; Zheng, JX | 1 |
| Blanchard, J; Gong, CX; Iqbal, K; Li, X; Li, Y; Liu, F; Yu, Y | 1 |
| Ahad, A; Ahsan, H; Mujeeb, M; Siddiqui, WA | 1 |
| Kuo, YH; Lin, CH; Shih, CC | 1 |
| Shieh, KR; Tseng, HL; Yang, SC; Yang, SH | 1 |
| Dong, X; Gao, D; Hao, G; Liu, Z; Meng, Z; Ning, N; Niu, X; Yang, G | 1 |
| Ho, HY; Jian, JY; Lin, CH; Shih, CC; Wu, JB | 1 |
| Akdag, H; Esen, A; Evcim, S; Gidener, S; Murat, N | 1 |
| Guo, DF; Liu, X; Lu, KT; Mukohda, M; Rahmouni, K; Sigmund, CD; Stump, M | 1 |
| Batatinha, HA; Biondo, LA; Lima, EA; Lira, FS; Rosa Neto, JC; Silveira, LS; Souza, CO; Teixeira, AA | 1 |
| Dong, Z; Duan, H; Ji, X; Jiang, P; Li, M; Li, X; Ma, B; Ma, X; Ni, Z; Wang, B; Wei, Q | 1 |
| Franceschi, RT; Ge, C; Hinds, TD; Lecka-Czernik, B; Sanchez, ER; Stechschulte, LA | 1 |
| Banz, WJ; Bollaert, M; Chickris, N; Higginbotham, A; Iqbal, MJ; Rockway, S | 1 |
| Choi, MS; Jeon, SM; Jeong, YJ; Kim, DJ; Kim, HJ; Kwon, JH; Lee, MK; Moon, KD; Park, YB | 1 |
| Fleckner, J; Larsen, LK; Larsen, PJ; Lykkegaard, K; Sauerberg, P; Wassermann, K; Wulff, EM | 1 |
| Brunani, A; Castagna, G; Gondoni, LA; Graci, S; Liuzzi, A; Titon, A; Viberti, GC | 1 |
| Araujo de Baptista, E; Baptista, T; Beaulieu, S; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E | 1 |
| Blanchard, PG; Brindley, DN; Deshaies, Y; Festuccia, WT; Laplante, M; Richard, D; Sariahmetoglu, M; Turcotte, V | 1 |
| Ahn, CW; Cha, BS; Kim, HJ; Kim, SK; Lee, HC; Lee, YJ; Ma, ZA; Shim, WS; Zhao, Z | 1 |
| Bebakar, WM; Brändle, M; Colagiuri, S; Kamaruddin, NA; Le Thi, TD; Marre, M; Shaw, J; Strand, J; Zdravkovic, M | 1 |
| Gupta, J; Kumar, P; Tikoo, K | 1 |
| Maldonado-Lutomirsky, M; Niggli, M; Rosenstock, J | 1 |
| Achouba, A; Arsenault, M; Brûlé, S; Couet, J; Deshaies, Y; Festuccia, WT; Guerra-Sá, R; Houde, VP; Lachance, D; Laplante, M; Marette, A; Pedrosa, ML; Silva, ME | 1 |
| Kang, JH; Park, HO; Yun, SI | 1 |
| Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ | 1 |
| Cockerill, GW; Deb, R; Dunkley, M; Gaze, D; Gnaneswaran, Y; Howe, F; Jones, A; Loftus, IM; Nasr, H; Thompson, MM; Torsney, E | 1 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Brath, H; Ludvik, B; Toplak, H; Wascher, T | 1 |
| Derosa, G; Maffioli, P; Tinelli, C | 1 |
| Chajut, A; Cooper, A; Lee, S; Leizerman, I; Molero, JC; Walder, K | 1 |
| Jones, AV; Lamarca, BB; Racusen, LC; Reckelhoff, JF; Romero, DG; Ryan, MJ; Sartori-Valinotti, JC; Venegas-Pont, MR; Yanes, LL | 1 |
| Baek, SH; Chang, K; Ihm, SH; Kim, HY; Kim, JH; Seung, KB; Youn, HJ | 1 |
| Devaskar, SU; Garg, M; Lee, PW; Pan, G; Thamotharan, M | 1 |
| Barros, CD; Couto, JA; Galdino, SL; Lima, MC; Peixoto, CA; Pitta, IR; Saraiva, KL; Udrisar, DP; Vieira, JS; Wanderley, MI | 1 |
| Aquilante, CL; Knutsen, SD; Kosmiski, LA; Rome, LC; Zineh, I | 1 |
| Ding, LJ; Ji, H; Ji, JL; Li, YQ; Liu, K; Ma, L; Yu, X | 1 |
| Blanchard, PG; Deshaies, Y; Festuccia, WT; Richard, D | 1 |
| Allen, K; Cali, AM; Caprio, S; Pierpont, BM; Savoye, M; Shaw, MM; Taksali, SE | 1 |
| Guo, X; Karathanasis, SK; Kassab, GS; Lu, X; Onyia, JE; Peterson, RG; Zimmerman, KM | 1 |
| Abassi, Z; Collins-Racie, L; Diblasio-Smith, L; Feuerstein, GZ; Goltsman, I; Lavallie, ER; Liu, X; Mounts, WM; Rutkowski, JL; Wang, X; Winaver, J; Xu, X; Zhan, Y | 1 |
| Gang, GT; Hwang, JH; Kim, YH; Lee, CH; Noh, JR; Yang, KJ; Yang, SJ; Yeom, YI | 1 |
| Chen, YT; Cheng, JT; Chi, TC; Lee, HH; Lo, SH; Yeh, CH | 1 |
| Beck-Nielsen, H; Christiansen, C; Gjessing, H; Gram, J; Grodum, E; Hangaard, J; Hansen, HM; Hansen, TB; Henriksen, JE; Juhl, H; Vestergaard, V; Yderstræde, K | 1 |
| Jue, D; Kraemer, FB; Liu, LF; Patel, S; Shen, WJ; Yu, Z | 1 |
| Chen, Q; Liu, B; Liu, S; Wu, HJ; Wu, JP; Zhang, ZQ; Zhu, L | 1 |
| Gerstein, HC; Hettinga, BP; Holloway, AC | 1 |
| El-Agamy, DS; Said, SA | 1 |
| Chen, W; Liu, HY; Wang, LL; Zhang, LH; Zhou, XB | 1 |
| Ayanoğlu-Dülger, G; Çelikel, Ç; Elçioğlu, HK; Kabasakal, L; Özkan, N | 1 |
| Dörffel, K; Haemmerle, G; Mayer, B; Schrammel, A; Wölkart, G; Zechner, R | 1 |
| Bastacky, S; Bilan, VP; Jones, HB; Mayers, RM; Poucher, SM; Salah, EM; Tofovic, SP; Zinker, B | 1 |
| Fan, MS; Huang, CG; Li, ZX; Sun, ZL; Tang, YH | 1 |
| Gierman, LM; Huizinga, TW; Kleemann, R; Kloppenburg, M; Kooistra, T; Koudijs, A; Stojanovic-Susulic, V; Stoop, R; van der Ham, F; van Osch, GJ; Wielinga, PY; Zuurmond, AM | 1 |
| Borsting, E; Cheng, VP; Cunard, R; Glass, CK; Vallon, V | 1 |
| Hu, W; Liu, D; Yu, Q; Zhang, J | 1 |
| Gao, W; Jusko, WJ | 1 |
| Choi, MS; Do, GM; Jeon, SM; Jung, UJ; Kwon, EY; McGregor, RA; Park, HJ | 1 |
| Haga, S; Ishibashi, Y; Ishida, H; Izawa, T; Kizaki, T; Ogasawara, J; Ohno, H; Radak, Z; Sakurai, T; Sumitani, Y | 1 |
| Du, Q; Fan, B; Wang, YJ; Wu, B; Yang, S; Zhao, YY | 1 |
| Harini, R; Pugalendi, KV; Sundaresan, A | 1 |
| Christensen, LP; Kristiansen, K; Rimbach, G; Schrader, E; Wein, S; Wolffram, S | 1 |
| Aston-Mourney, K; Brooks-Worrell, BM; Hull, RL; Subramanian, SL; Taborsky, GJ; Udayasankar, J; Zraika, S | 1 |
| Hirvonen, J; Jänne, OA; Mikkonen, L | 1 |
| Muthulakshmi, S; Saravanan, R | 1 |
| Li, M; Lin, Y; Ma, Y; Zheng, Z | 1 |
| Chen, H; Freed, MI; Greenberg, AS; Haffner, SM; Weston, WM; Williams, K | 1 |
| Aleksunes, LM; Reagan, LA; Vergara, CM; Wang, F | 1 |
| Hällsten, K; Knuuti, J; Lönnqvist, F; Nuutila, P; Oksanen, A; Rönnemaa, T; Sipilä, H; Viikari, J; Viljanen, T; Virtanen, KA | 1 |
| Andersen, B; Brand, CL; Fleckner, J; Fledelius, C; Gotfredsen, CF; Hansen, BF; Sauerberg, P; Sturis, J; Wassermann, K; Ye, JM | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Lavoie, MF; Schiffrin, EL; Touyz, RM | 1 |
| Cleasby, ME; Livingstone, DE; Nyirenda, MJ; Seckl, JR; Walker, BR | 1 |
| Hällsten, K; Huupponen, R; Janatuinen, T; Knuuti, J; Lönnqvist, F; Lönnroth, P; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, T; Virtanen, KA | 1 |
| Bacon, BR; Brunt, EM; Hampton, K; Neuschwander-Tetri, BA; Sponseller, CA; Wehmeier, KR | 1 |
| Chao, L; Chen, Y; Choi, H; Fillmore, JJ; Gavrilova, O; Haluzik, M; Higashimori, T; Kim, HJ; Kim, JK; Qu, X; Reitman, ML; Shulman, GI; Yu, C | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC | 1 |
| Havekes, LM; Mensink, RP; Muurling, M; Pijl, H; Romijn, JA; Voshol, PJ | 1 |
| Narce, M; Poisson, JP | 1 |
| Barnes, GT; Chen, H; Chou, CJ; Nichols, A; Ross, JS; Sole, J; Tan, G; Tartaglia, LA; Xu, H; Yang, D; Yang, Q | 1 |
| Battell, ML; Bhanot, S; McNeill, JH; Orvig, C; Yuen, VG | 1 |
| Desouza, CV; Diez, J; Dunne, B; Fonseca, VA; Matta, AS; McNamara, DB; Murthy, SN | 1 |
| Cline, GW; Davies, PJ; Leibowitz, MD; Shen, Q; Shulman, GI | 1 |
| Bouffard, L; Maheux, P; St-Pierre, P | 1 |
| Aguilar, E; Barreiro, ML; Caminos, JE; Casanueva, FF; Diéguez, C; Gaytán, F; Navarro, VM; Nogueiras, R; Suominen, JS; Tena-Sempere, M; Toppari, J | 1 |
| Collins, JN; Gee, MK; Kauffman, RF; Rankin, SE; Wagner, JD; Zhang, L | 1 |
| Chiquette, E; Defronzo, R; Ramirez, G | 1 |
| Füchtenbusch, M; Löbner, K | 1 |
| Kneissel, M; Seuwen, K; Sottile, V | 1 |
| Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Tarim, E; Zeyneloglu, HB | 1 |
| McCluskey, D; Melis, R; Schleusener, DS; Touger, MS | 1 |
| Arch, JR; Augstein, P; Cawthorne, MA; Demuth, HU; Heinke, P; Hoffmann, T; Meyer, A; Sennitt, MV; Stocker, C; Subramanian, A; Wargent, E | 1 |
| Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Lokhandwala, MF; Trivedi, M | 1 |
| Ecelbarger, CA; Hu, X; Khan, O; Riazi, S; Song, J; Wade, JB | 1 |
| Barr, R; Bensch, WR; Brozinick, JT; Bull, C; Dana, S; Hawkins, E; Klausing, K; Martin, JA; Otto, K; Rafaeloff-Phail, R; Rafizadeh-Montrose, C; Reifel-Miller, A; Rhodes, G; Robey, R; Rojo, I; Rungta, D; Snyder, D; Warshawsky, A; Wilbur, K; Zhang, T; Zink, R | 1 |
| Chen, D; Chen, TJ; Chen, X; Fang, W; Lü, SZ; Mi, SH; Shi, Q; Song, AL; Wang, LY; Wang, W; Wu, Y; Xu, JP; Yan, D; Zhao, QM | 1 |
| Gonzalez, FJ; Kohan, DE; Nelson, RD; Yang, T; Zhang, A; Zhang, H | 1 |
| Cantürk, Z; Cetinarslan, B; Komsuoglu, B; Sahin, T; Tarkun, I; Türemen, E | 1 |
| Alegret, M; Laguna, JC; Roglans, N; Sánchez, RM; Sanguino, E; Vázquez-Carrera, M | 1 |
| Barbe, J; Galdino, SL; Lima, MC; Lima, VL; Mourão, RH; Pitta, IR; Santos, JN; Silva, TG; Soares, AL; Vieira, ES | 1 |
| Arslan, M; Ayvaz, G; Bukan, N; Cakir, N; Karakoç, A; Törüner, F; Yilmaz, M | 1 |
| Baik, SH; Choi, DS; Choi, KC; Choi, KM; Kim, HY; Kim, NH; Kim, SG; Lee, KW; Ryu, OH; Seo, JA | 1 |
| Dehmel, B; Petzoldt, R; Reblin, T; Rosak, C; Seidel, D; Wolf, R | 1 |
| Adler, S; Banz, WJ; Davis, J; Henry, N; Higginbotham, DA; Hou, Y; Meyers, CY; Oitker, J; Peterson, R; Steinle, JJ; Winters, TA | 1 |
| Bloedon, LT; Iqbal, N; Kochar, A; Rader, DJ; Samaha, FF; Szapary, PO; Williams, MM; Wolfe, ML | 1 |
| Bruce, S; Garber, A; Klein, E; Mohideen, P; Sankoh, S | 1 |
| Antoine, B; Chapron, C; Chauvet, G; Forest, C; Leroyer, SN; Quette, J; Tordjman, J | 1 |
| Houstis, N; Lander, ES; Rosen, ED | 1 |
| Kurosaki, E; Maruyama, T; Nakano, R; Shibasaki, M; Shimaya, A; Yokono, M; Yoshida, S | 1 |
| Geng, DF; Jin, DM; Wang, JF; Wu, W; Wu, YM | 1 |
| Ahn, CW; Cha, BS; Do, MY; Hur, KY; Kang, ES; Kim, HJ; Kim, SK; Lee, HC; Lim, SK; Shim, WS | 1 |
| Gonzalez, FJ; Morimura, K; Shah, YM | 1 |
| Marasciulo, FL; Montagnani, M; Potenza, MA; Quon, MJ; Tarquinio, M | 1 |
| Bansal, VS; Bora, RS; Gupta, A; Khanna, V; Khattar, SK; Mittra, S; Priyadarsiny, P; Roy, S; Saini, KS; Sangle, G; Sattigeri, J; Sharma, L; Sharma, S; Tandon, R | 1 |
| Belury, MA; Liu, LF; Purushotham, A; Wendel, AA | 1 |
| Asano, S; Hansen, MK; Higashiyama, H; Kinoshita, M; McVey, MJ; Okamoto, Y; Rong, JX | 1 |
| Ahn, CW; Cha, BS; Jung, TW; Kang, ES; Kim, DJ; Kim, HJ; Lee, HC; Lee, KW | 1 |
| Bansal, VS; Davis, JA; Dhar, A; Khanna, V; Mahajan, DC; Mittra, S; Priyadarsiny, P; Roy, S; Saini, KS; Sattigeri, J; Singh, S | 1 |
| Baek, NI; Bang, MH; Choi, MS; Chung, HG; Jeong, TS; Jung, UJ; Kang, YJ; Kim, HJ; Lee, KT; Lee, MK; Yeo, JY; Yoo, JS | 1 |
| Hawley, JA; Kvasha, I; Lessard, SJ; Limon, JJ; Reeder, DW; Rivas, DA; Saito, M; Yaspelkis, BB | 1 |
| Díaz-Sanjuán, T; García-Ruiz, I; Martínez, MA; Muñoz-Yagüe, T; Rodríguez-Juan, C; Solís-Herruzo, JA | 1 |
| Bence, KK; Delibegovic, M; Hong, EG; Kahn, BB; Kim, JK; Ko, HJ; Mody, N; Neel, BG | 1 |
| Ferrante, AW; Johnson, JA; Trasino, SE; Vasselli, JR | 1 |
| Hong, LZ; Hsieh, PS | 1 |
| Atkin, SL; Cho, LW | 1 |
| Davies, MJ; Engel, SS; Loeys, T; Scott, R | 1 |
| Banks, WA; Bartness, TJ; Berthiaume, M; Brito, MN; Brito, NA; Denis, RG; Deshaies, Y; Dohgu, S; Festuccia, WT; Laplante, M; Michel, C; Miller, DS; Oztezcan, S; Richard, D | 1 |
| Doggrell, SA | 1 |
| Ayaz, L; Emre, M; Günay, I; Inal, T; Kavak, S; Tamer, L | 1 |
| Bellmann, K; Centeno-Baez, C; Dallaire, P; Deshaies, Y; Gélinas, S; Lamontagne, J; Laplante, M; Latour, MG; Marette, A; Penfornis, P; Peyot, ML; Prentki, M; Scherer, PE; Trujillo, ME | 1 |
| Bing, C; Buckingham, R; Dryden, S; Frankish, HM; Hopkins, D; Pickavance, L; Wang, Q; Williams, G | 1 |
| Al-Barazanji, KA; Bond, B; Buckingham, RE; Clapham, JC; Connor, SC; Slaughter, M; Toseland, CD; Turner, NC; West, A | 1 |
| Akanuma, Y; Ide, T; Kadowaki, T; Mochizuki, T; Murakami, K; Ohashi, M; Tobe, K; Yazaki, Y | 1 |
| Buckingham, RE; Pickavance, LC; Tadayyon, M; Widdowson, PS; Wilding, JP | 1 |
| Chaput, E; Edgar, AD; Saladin, R; Silvestre, M | 1 |
| King, AB | 1 |
| Cawthorne, MA; Crombie, DL; Heyman, RA; Hislop, DC; Liu, YL; Sennitt, MV | 1 |
| Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S | 1 |
| Anderson, RJ; Patel, J; Rappaport, EB | 1 |
| Collins, AR; Hsueh, WA; Jackson, S; Kintscher, U; Law, RE; Meehan, WP; Noh, G; Palinski, W; Wakino, S | 1 |
| Buckingham, RE; Finegood, DT; Kojwang, D; Leonard, T; McArthur, MD; Thomas, MJ; Topp, BG | 1 |
| Jacinto, SM; Ljung, B; Oakes, ND; Thalén, PG | 1 |
| Buckingham, RE; Pickavance, LC; Wilding, JP | 1 |
| Auwerx, J; Bac, P; Blanchard, SG; Champy, MF; Desreumaux, P; Dubuquoy, L; Gelman, L; Leesnitzer, LM; Moras, D; Picard, F; Plunket, KD; Potier, N; Renaud, JP; Rocchi, S; Vamecq, J; Zeyer, D | 1 |
| Adler, A; Bush, E; Kramer, D; Rondinone, CM; Shapiro, R | 1 |
| Brunmair, B; Fürnsinn, C; Gras, F; Nowotny, P; Roden, M; Vierhapper, H; Waldhäusl, W | 1 |
| Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H | 1 |
| Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ | 1 |
| Amiri, F; Cohn, JS; Diep, QN; El Mabrouk, M; Endemann, D; Neves, MF; Schiffrin, EL; Virdis, A | 1 |
| Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM | 1 |
9 review(s) available for rosiglitazone and Body Weight
| Article | Year |
|---|---|
Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Body Weight; Female; Humans; Hypoglycemic Agents; Metformin; Orlistat; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone | 2022 |
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone | 2019 |
Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.
Topics: Androgens; Blood Glucose; Body Weight; Female; Humans; Insulin; Insulin Resistance; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2012 |
Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Topics: Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diuresis; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Glucose; Body Weight; C-Reactive Protein; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exercise; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Research; Risk Factors; Rosiglitazone; Thiazolidinediones | 2004 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Weight Loss | 2007 |
Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
Topics: Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2008 |
20 trial(s) available for rosiglitazone and Body Weight
| Article | Year |
|---|---|
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Double-Blind Method; Female; Fibrinogen; Hemoglobins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Olanzapine; Pilot Projects; Rosiglitazone; Schizophrenia; Statistics as Topic; Thiazolidinediones | 2009 |
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Drug Utilization; Female; Fractures, Bone; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Neoplasms; Prospective Studies; Rosiglitazone; Sex Factors; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Resistin; Rosiglitazone; Thiazolidinediones; Time Factors; Waist Circumference | 2010 |
Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study.
Topics: Adolescent; Body Composition; Body Weight; Double-Blind Method; Female; Glucose; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Obesity; Patient Compliance; Pilot Projects; Placebos; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones | 2011 |
[Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome].
Topics: Administration, Oral; Adult; Androstenedione; Blood Glucose; Body Weight; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Lipids; Luteinizing Hormone; Menstruation; Neuropeptide Y; Ovulation; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Interleukin-6; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Receptors, Cytoplasmic and Nuclear; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exercise; Fasting; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Leg; Male; Metformin; Middle Aged; Muscle, Skeletal; Oxygen Consumption; Radionuclide Imaging; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Topics: Adipose Tissue; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lactates; Lipids; Male; Metformin; Middle Aged; Placebos; Radiopharmaceuticals; Rosiglitazone; Thiazoles; Thiazolidinediones; Tomography, Emission-Computed; Weight Loss | 2003 |
Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight; Fatty Liver; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Male; Middle Aged; Patient Dropouts; Pilot Projects; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2003 |
Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Topics: Adult; Anovulation; Blood Glucose; Body Weight; Female; Folic Acid; Homocysteine; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazolidinediones; Vitamin B 12 | 2005 |
Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.
Topics: Adult; Biomarkers; Body Weight; C-Reactive Protein; Endothelium, Vascular; Female; Hormones; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle, Smooth, Vascular; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Vasculitis | 2005 |
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Antioxidants; Blood Glucose; Body Mass Index; Body Weight; Female; Homeostasis; Homocysteine; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Malondialdehyde; Metformin; Models, Statistical; Oxidative Stress; Polycystic Ovary Syndrome; Risk Factors; Rosiglitazone; Smoking; Thiazolidinediones; Time Factors | 2005 |
Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Topics: Adiponectin; Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Pressure; Body Weight; C-Reactive Protein; Cholesterol, HDL; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Receptors, Tumor Necrosis Factor, Type II; Resistin; Rosiglitazone; Thiazolidinediones | 2006 |
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Rosiglitazone; Tablets; Thiazolidinediones; Treatment Outcome | 2006 |
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides | 2008 |
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
148 other study(ies) available for rosiglitazone and Body Weight
| Article | Year |
|---|---|
Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
Topics: Animals; Blood Glucose; Body Weight; Cell Line, Tumor; Diabetes Mellitus; Ether; Humans; Hypoglycemic Agents; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Structure-Activity Relationship; Thiazolidinediones | 2006 |
Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
Topics: Animals; Blood Glucose; Body Weight; Cell Line, Tumor; Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Structure-Activity Relationship | 2006 |
Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Body Weight; Diabetes Mellitus, Experimental; Fats; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Mice; Models, Molecular; Obesity; Phenylpropionates; PPAR gamma; Rats; Rats, Wistar | 2009 |
Synthesis of a new [6]-gingerol analogue and its protective effect with respect to the development of metabolic syndrome in mice fed a high-fat diet.
Topics: Acetyl-CoA Carboxylase; Adiponectin; Adipose Tissue; Amides; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Catechols; Dietary Fats; Energy Metabolism; Fatty Alcohols; Glucose Tolerance Test; Guaiacol; Insulin; Leptin; Lipogenesis; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred ICR; RNA, Messenger; Sterol Regulatory Element Binding Protein 1 | 2011 |
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Partial Agonism; Drug Screening Assays, Antitumor; Fibric Acids; Fibroblasts; Gene Expression Profiling; Humans; Insulin Resistance; Intra-Abdominal Fat; Liver; Mice; Mice, Inbred C57BL; Models, Molecular; PPAR alpha; PPAR gamma; Propionates; Stereoisomerism; Structure-Activity Relationship; Urea | 2012 |
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Female; Glucose; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tissue Distribution; Triglycerides | 2012 |
A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-A
Topics: Adipose Tissue; Alanine Transaminase; alpha-Glucosidases; Animals; Aspartate Aminotransferases; Blood Glucose; Body Weight; Female; Ganoderma; Glycogen; Glycoside Hydrolase Inhibitors; Hydroquinones; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Kinetics; Liver; Male; Mice; Molecular Docking Simulation; Protein Conformation | 2017 |
Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
Topics: Animals; Body Weight; Caloric Restriction; Cells, Cultured; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Gene Expression Profiling; Hypoglycemic Agents; Immediate-Early Proteins; Ligands; Male; Mice; Mice, Obese; Molecular Docking Simulation; Molecular Structure; PPAR gamma; Protein Serine-Threonine Kinases; Sirtuin 1; Structure-Activity Relationship | 2017 |
The effect of sitagliptin combined with rosiglitazone on autophagy and inflammation in polycystic ovary syndrome by regulating PI3K/AKT/mTOR and TLR4/NF-κB pathway.
Topics: Animals; Autophagy; Blood Glucose; Body Weight; Female; Gonadal Steroid Hormones; Inflammation; Insulins; Interleukin-18; Interleukin-6; NF-kappa B; Phosphatidylinositol 3-Kinases; Polycystic Ovary Syndrome; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; Rosiglitazone; Toll-Like Receptor 4; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2023 |
A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy.
Topics: Animals; Body Weight; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Movement; Dasatinib; Drug Carriers; Drug Delivery Systems; Drug Liberation; Endocytosis; Female; Hemolysis; Humans; Hyaluronic Acid; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Particle Size; Proton Magnetic Resonance Spectroscopy; Rats, Sprague-Dawley; Rosiglitazone; Static Electricity; Tissue Distribution; Tumor Burden | 2021 |
Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
Topics: Animals; Body Weight; Diet, High-Fat; Fatty Acids; Gynostemma; Lipogenesis; Liver; Liver Function Tests; Male; Non-alcoholic Fatty Liver Disease; Organ Size; Oxidation-Reduction; Plant Extracts; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2017 |
Rosiglitazone Improves Insulin Resistance Mediated by 10,12 Conjugated Linoleic Acid in a Male Mouse Model of Metabolic Syndrome.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Disease Models, Animal; Glucose; Insulin Resistance; Linoleic Acids, Conjugated; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2017 |
PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects.
Topics: Acetylation; Adipose Tissue, White; Animals; Body Weight; Energy Metabolism; Female; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Transgenic; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2018 |
Co-administration of conjugated linoleic acid and rosiglitazone increases atherogenic co-efficient and alters isoprenaline-induced vasodilatation in rats fed high fat diet.
Topics: Adrenergic beta-Agonists; Animals; Atherosclerosis; Blood Glucose; Body Weight; Diet, High-Fat; Isoproterenol; Linoleic Acids, Conjugated; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Vasodilation | 2018 |
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis.
Topics: Adipose Tissue; Animals; Biomarkers; Blood Glucose; Body Weight; Diet, High-Fat; Disease Models, Animal; Glucose Intolerance; Hepatocytes; Lipid Metabolism; Male; Mice; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Obesity; Oleic Acids; Protective Agents; Rosiglitazone; Triglycerides | 2019 |
Resistin production from adipose tissue is decreased in db/db obese mice, and is reversed by rosiglitazone.
Topics: Adiponectin; Adipose Tissue; Animals; Body Weight; Gene Expression Regulation; Immunoassay; Mice; Mice, Obese; Real-Time Polymerase Chain Reaction; Resistin; Rosiglitazone; Thiazolidinediones | 2013 |
Effect of Urtica dioica on memory dysfunction and hypoalgesia in an experimental model of diabetic neuropathy.
Topics: Animals; Avoidance Learning; Blood Glucose; Body Weight; Diabetic Neuropathies; Drug Therapy, Combination; Insulin; Maze Learning; Memory Disorders; Mice; Pain Threshold; Phytotherapy; Plant Extracts; Plant Leaves; Polydipsia; Rosiglitazone; Streptozocin; Thiazolidinediones; Urtica dioica | 2013 |
Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model.
Topics: Adipose Tissue; Animals; Biomarkers; Body Weight; Cachexia; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Imidazolidines; Inflammation Mediators; Insulin; Male; Mice; Muscle Proteins; Muscles; Muscular Atrophy; Neoplasms; Organ Size; Rosiglitazone; SKP Cullin F-Box Protein Ligases; Thiazolidinediones; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Protein Ligases | 2014 |
Rosiglitazone attenuates casein-induced hepatic endoplasmic reticulum stress in Sprague-Dawley rats: a novel model of endoplasmic reticulum stress.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Body Weight; Caseins; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Endoplasmic Reticulum Stress; Inflammation; Liver; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2013 |
Disparity in actions of rosiglitazone against cisplatin-induced nephrotoxicity in female Sprague-Dawley rats.
Topics: Animals; Antineoplastic Agents; Blood Urea Nitrogen; Body Weight; Cisplatin; Creatinine; Female; Hypoglycemic Agents; Kidney; Kidney Diseases; Kidney Function Tests; Organ Size; Rats; Rats, Sprague-Dawley; Rosiglitazone; Serum Albumin; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Antihyperglycemic effect of carvacrol in combination with rosiglitazone in high-fat diet-induced type 2 diabetic C57BL/6J mice.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Cymenes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Monoterpenes; Rosiglitazone; Thiazolidinediones | 2014 |
Fucosylated chondroitin sulfate from sea cucumber in combination with rosiglitazone improved glucose metabolism in the liver of the insulin-resistant mice.
Topics: Animals; Blood Glucose; Body Weight; Chondroitin Sulfates; Diet, High-Fat; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Glucose Tolerance Test; Glucose-6-Phosphatase; Glycogen; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hexokinase; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyruvate Kinase; Receptor, Insulin; Rosiglitazone; Sea Cucumbers; Signal Transduction; Thiazolidinediones | 2013 |
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Humulus; Hypoglycemic Agents; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Monocytes; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
[The protective effects of rosiglitazone on kidney in diet-induced obese rats].
Topics: Animals; Body Weight; Diet, High-Fat; Fatty Acids, Nonesterified; Intra-Abdominal Fat; Kidney Glomerulus; Nitric Oxide; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Triglycerides; Vascular Endothelial Growth Factor A; Vasodilation | 2014 |
Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats (PPAR γ).
Topics: Animals; Body Weight; Cardiomyopathies; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Insulin; Male; Myocardium; Myocytes, Cardiac; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2015 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Huntington Disease; Male; Maze Learning; Motor Activity; Neurodegenerative Diseases; Neuroprotective Agents; Neurotoxicity Syndromes; PPAR gamma; Quinolinic Acid; Rats, Wistar; Rosiglitazone; Signal Transduction; Thiazolidinediones; Valproic Acid | 2014 |
Exendin-4 shows no effects on the prostatic index in high-fat-diet-fed rat with benign prostatic hyperplasia by improving insulin resistance.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Exenatide; Glucagon-Like Peptide-1 Receptor; Insulin Resistance; Male; Peptides; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Receptors, Glucagon; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Venoms | 2015 |
Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.
Topics: Alzheimer Disease; Animals; Body Weight; Brain; Disease Models, Animal; Exploratory Behavior; Female; Hypoglycemic Agents; Learning Disabilities; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neuroimmunomodulation; Neuroprotective Agents; Nootropic Agents; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rosiglitazone; Spatial Learning; tau Proteins; Thiazolidinediones | 2015 |
Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Blood Glucose; Blotting, Western; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, High-Fat; Eating; Flavanones; Hypoglycemic Agents; Kidney; Male; NF-kappa B; Nitric Oxide Synthase Type II; Rats, Wistar; Rosiglitazone; Streptozocin; Thiazolidinediones; Transforming Growth Factor beta1; Treatment Outcome | 2014 |
Effects of Bofu-Tsusho-San on diabetes and hyperlipidemia associated with AMP-activated protein kinase and glucose transporter 4 in high-fat-fed mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, High-Fat; Down-Regulation; Drugs, Chinese Herbal; Fatty Acid Synthases; Gluconeogenesis; Glucose Transporter Type 4; Hyperlipidemias; Liver; Male; Mice; Mice, Inbred C57BL; Phosphorylation; PPAR alpha; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones | 2014 |
Hepatic circadian-clock system altered by insulin resistance, diabetes and insulin sensitizer in mice.
Topics: Animals; Blood Glucose; Body Weight; Circadian Clocks; Diabetes Mellitus, Experimental; Fasting; Female; Gene Expression Regulation; Glucose Tolerance Test; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Pregnancy; Rosiglitazone; Thiazolidinediones | 2015 |
Rosiglitzone suppresses angiotensin II-induced production of KLF5 and cell proliferation in rat vascular smooth muscle cells.
Topics: Angiotensin II; Anilides; Animals; Blood Pressure; Body Weight; Cell Proliferation; Cells, Cultured; Cyclin D1; Gene Expression Regulation; Hypoglycemic Agents; Kruppel-Like Transcription Factors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Phosphorylation; PPAR gamma; Prostaglandin D2; Protein Kinase C; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2015 |
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana, Prevents Diabetes and Hyperlipidemia by Regulation of Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Plants, Medicinal; Rosiglitazone; Thiazolidinediones | 2015 |
Acute effect of rosiglitazone on relaxation responses in hypercholesterolemic corpus cavernosum.
Topics: Acetylcholine; Animals; Body Weight; Cholesterol, Dietary; Endothelium, Vascular; Hypercholesterolemia; Hypoglycemic Agents; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Penis; PPAR gamma; Rabbits; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2016 |
Effect of selective expression of dominant-negative PPARγ in pro-opiomelanocortin neurons on the control of energy balance.
Topics: 3T3 Cells; Adipogenesis; Animals; Body Weight; Brain; Cell Line; Diet, High-Fat; Energy Metabolism; Female; HEK293 Cells; Homeostasis; Humans; Leptin; Male; Mice; Neurons; Obesity; PPAR gamma; Pro-Opiomelanocortin; Rosiglitazone; Thiazolidinediones; Weight Gain | 2016 |
Association Between Aerobic Exercise and Rosiglitazone Avoided the NAFLD and Liver Inflammation Exacerbated in PPAR-α Knockout Mice.
Topics: Animals; Body Weight; Disease Progression; Fasting; Inflammation; Lipids; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Organ Size; Phosphorylation; Physical Conditioning, Animal; PPAR alpha; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2017 |
Effect of Vanadyl Rosiglitazone, a New Insulin-Mimetic Vanadium Complexes, on Glucose Homeostasis of Diabetic Mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Drinking Behavior; Feeding Behavior; Homeostasis; Insulin; Male; Metformin; Mice; Quercetin; Rosiglitazone; Spectrophotometry, Infrared; Thiazolidinediones; Trehalose; Vanadium | 2016 |
Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2).
Topics: Active Transport, Cell Nucleus; Animals; Body Weight; Bone and Bones; Cell Nucleus; Core Binding Factor Alpha 1 Subunit; Glycoproteins; Male; Mesenchymal Stem Cells; Mice; Mice, Knockout; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2016 |
A combination of CLA-DAG oil modifies the diabetic phenotype in male Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diglycerides; DNA, Complementary; Eating; Gene Expression; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney; Linoleic Acid; Liver; Muscle, Skeletal; Myocardium; Phenotype; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Beneficial effect of chungkukjang on regulating blood glucose and pancreatic beta-cell functions in C75BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fermentation; Glucagon; Glucokinase; Glycated Hemoglobin; Glycine max; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Isoflavones; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Pancreas; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2008 |
Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Topics: Adipogenesis; Adipose Tissue; Animals; Blood Volume; Body Weight; Drinking; Eating; Heart; Humans; Hypoglycemic Agents; Male; Mice; Organ Size; PPAR gamma; Quinazolines; Rats; Rosiglitazone; Thiazolidinediones | 2008 |
Evaluation of rosiglitazone administration on cardiovascular function in severe obesity.
Topics: Adult; Blood Pressure; Body Weight; Cardiovascular System; Diastole; Echocardiography, Doppler; Female; Humans; Insulin; Insulin Resistance; Male; Obesity; PPAR gamma; Rosiglitazone; Systole; Thiazolidinediones; Ventricular Function, Left | 2008 |
The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake.
Topics: Adipose Tissue, Brown; Animals; Blood Glucose; Body Weight; Diacylglycerol O-Acyltransferase; Energy Metabolism; Glucose; Glycogen; Hypoglycemic Agents; Insulin; Lactates; Lipogenesis; Male; Models, Animal; Pancreatitis-Associated Proteins; PPAR gamma; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides | 2009 |
Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Diabetes Mellitus, Experimental; Diet; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Male; Malonyl Coenzyme A; Muscle, Skeletal; Rats; Rats, Inbred OLETF; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Blotting, Western; Body Weight; Cisplatin; Creatinine; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Histones; Kidney; Kidney Diseases; Mammary Glands, Animal; Mammary Neoplasms, Experimental; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Serum Albumin; Thiazolidinediones; Tumor Burden; Tumor Necrosis Factor-alpha | 2009 |
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vildagliptin; Weight Gain | 2009 |
Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation.
Topics: Animals; Atrial Natriuretic Factor; Blotting, Western; Body Weight; Cardiomegaly; Eating; Echocardiography; Glucosyltransferases; Glycogen; Glycogen Phosphorylase; Glycogen Synthase; Glycoproteins; Hemodynamics; Hypoglycemic Agents; Lipoprotein Lipase; Male; Myofibrils; Natriuretic Peptide, Brain; Proteasome Endopeptidase Complex; Protein Kinases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; TOR Serine-Threonine Kinases; UTP-Glucose-1-Phosphate Uridylyltransferase | 2009 |
Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Lactobacillus; Male; Mice; Mice, Inbred C57BL; Milk, Human; Models, Animal; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Blood Glucose; Body Weight; Cholesterol; Disease Models, Animal; E-Selectin; Humans; Hypercholesterolemia; Hypoglycemic Agents; Interleukin-6; Mice; Mice, Knockout; PPAR gamma; Receptors, Angiotensin; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2009 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus].
Topics: Austria; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Long-Acting; Myocardial Infarction; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2009 |
Effects of rosiglitazone on intramyocellular lipid accumulation in Psammomys obesus.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Dietary Carbohydrates; Gerbillinae; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin; Intracellular Space; Lipids; Male; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats.
Topics: Albuminuria; Animals; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Chemokine CCL2; Cholesterol; Estradiol; Feeding Behavior; Female; Gene Expression Regulation; Immunohistochemistry; Inflammation; Insulin; Kidney; Leptin; Nitrates; Nitrites; Osteopontin; Ovariectomy; Rats; Rats, Inbred Dahl; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2010 |
Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Topics: Animals; Body Weight; Cardiomyopathies; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Fibrosis; Glucose Tolerance Test; Male; Myocardium; PPAR gamma; Rats; Rats, Inbred OLETF; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones | 2010 |
Early exposure of the pregestational intrauterine and postnatal growth-restricted female offspring to a peroxisome proliferator-activated receptor-{gamma} agonist.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Humans; PPAR gamma; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2010 |
Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studies.
Topics: Animals; Body Weight; Cells, Cultured; Cholesterol Side-Chain Cleavage Enzyme; Drug Evaluation, Preclinical; Hypoglycemic Agents; Leydig Cells; Male; Organ Size; Phosphoproteins; Rats; Rats, Wistar; Rosiglitazone; Seminal Vesicles; Steroids; Testis; Testosterone; Thiazolidinediones; Time Factors | 2010 |
Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Biomechanical Phenomena; Blood Pressure; Body Weight; Bone Density; Bone Remodeling; Bone Resorption; Female; Heart Rate; Lumbar Vertebrae; Ovariectomy; Rats; Rats, Inbred SHR; Rosiglitazone; Systole; Telmisartan; Thiazolidinediones; Tibia; Time Factors; X-Ray Microtomography | 2010 |
Basal adrenergic tone is required for maximal stimulation of rat brown adipose tissue UCP1 expression by chronic PPAR-gamma activation.
Topics: Adipose Tissue, Brown; Adrenergic Agents; Animals; Apoptosis Regulatory Proteins; Body Weight; Cell Line; Diacylglycerol O-Acyltransferase; Fatty Acid-Binding Proteins; Ion Channels; Male; Mitochondrial Proteins; Norepinephrine; PPAR alpha; PPAR gamma; Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thermogenesis; Thiazolidinediones; Uncoupling Protein 1 | 2010 |
Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats.
Topics: Adiposity; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Femoral Artery; Hypoglycemic Agents; Matrix Metalloproteinase 9; Myography; Nitric Oxide Synthase Type III; Pancreatic Elastase; Rats; Rats, Zucker; Receptors, Adrenergic, alpha; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2010 |
Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.
Topics: Animals; Biomarkers; Body Weight; Diabetes Mellitus; Echocardiography; Fibrosis; Gene Expression Regulation; Heart Failure; Hemodynamics; Hypoglycemic Agents; Immunohistochemistry; Myocarditis; Myocardium; Organ Size; PPAR gamma; Rats; Rats, Inbred Lew; Rats, Zucker; RNA; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical | 2010 |
Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.
Topics: Acyl-CoA Dehydrogenase; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; CD36 Antigens; Cholesterol; Diabetes Mellitus, Experimental; Diacylglycerol O-Acyltransferase; Fatty Acid Transport Proteins; Gene Expression Regulation; Hypoglycemic Agents; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides | 2010 |
Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice.
Topics: Animals; Body Weight; Cardiomegaly; Drug Therapy, Combination; Eating; Male; Metformin; Mice; Mice, Inbred BALB C; Obesity; Rosiglitazone; Thiazolidinediones; Weight Gain | 2010 |
Hormone-sensitive lipase modulates adipose metabolism through PPARγ.
Topics: Adipogenesis; Adipose Tissue; Animals; Antigens, Differentiation; Body Weight; Dietary Fats; Gene Expression Profiling; Gene Expression Regulation; Glucose Tolerance Test; Hypoglycemic Agents; Lipolysis; Mice; Mice, Knockout; PPAR gamma; Rosiglitazone; Sterol Esterase; Thiazolidinediones | 2011 |
The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats.
Topics: Adiponectin; Adipose Tissue; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Fatty Liver; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
Topics: Adiposity; Analysis of Variance; Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Metformin; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2011 |
Prevention of sodium valproate-induced hepatotoxicity by curcumin, rosiglitazone and N-acetylcysteine in rats.
Topics: Acetylcysteine; Animals; Anticonvulsants; Body Weight; Chemical and Drug Induced Liver Injury; Convulsants; Curcumin; Eating; Fatty Liver; Free Radical Scavengers; Hypoglycemic Agents; Liver; Liver Function Tests; Male; Mice; Pentylenetetrazole; Rats; Rats, Sprague-Dawley; Rosiglitazone; Seizures; Thiazolidinediones; Valproic Acid | 2010 |
Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Weight; Drug Synergism; Eating; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipids; Lipoprotein Lipase; Liver; Metabolic Syndrome; Mice; Mice, Inbred ICR; RNA, Messenger; Rosiglitazone; Sodium Glutamate; Thiazolidinediones | 2010 |
A study comparing the effects of rosiglitazone and/or insulin treatments on streptozotocin induced diabetic (type I diabetes) rat aorta and cavernous tissues.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glutathione; Inflammation; Insulin; Lipid Peroxidation; Male; Muscle Relaxation; Penis; Rats; Rosiglitazone; Thiazolidinediones | 2011 |
Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist.
Topics: Animals; Anticholesteremic Agents; Body Weight; Female; Heart; Heart Rate; In Vitro Techniques; Lipase; Male; Mice; Mice, Knockout; Myocardium; Norepinephrine; Organ Size; PPAR alpha; PPAR gamma; Pyrimidines; Rosiglitazone; Thiazolidinediones; Ventricular Dysfunction, Left | 2012 |
Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetic Nephropathies; Disease Models, Animal; Enalapril; Humans; Hypoglycemic Agents; Kidney; Liver; Male; Metabolic Syndrome; Myocardium; Obesity; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones | 2011 |
Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice.
Topics: Acrolein; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Cholesterol, HDL; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucose Intolerance; Glycated Hemoglobin; Hypoglycemic Agents; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Phytotherapy; Rosiglitazone; Saponins; Thiazolidinediones; Triglycerides; Xanthones | 2012 |
Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice.
Topics: Animals; Body Weight; C-Reactive Protein; Cytokines; Diet, High-Fat; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Insulin; Male; Mice; Mice, Transgenic; Obesity; Osteoarthritis; Pyrimidines; Rosiglitazone; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones | 2012 |
Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.
Topics: Abdominal Fat; Acetylation; Animals; Body Weight; Epithelial Sodium Channels; Hypoglycemic Agents; Kidney; Mice; Pioglitazone; PPAR gamma; Promoter Regions, Genetic; Rosiglitazone; Thiazolidinediones | 2012 |
Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.
Topics: Adipokines; Animals; Blood Glucose; Body Weight; Chemokines; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Kidney; Male; Pioglitazone; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Chemokine; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2012 |
Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Male; Random Allocation; Rats; Rosiglitazone; Thiazolidinediones | 2012 |
Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dietary Supplements; Dyslipidemias; Glucose Transporter Type 4; Glycated Hemoglobin; Glycogen; Insulin; Insulin Secretion; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscle, Skeletal; Resveratrol; Rosiglitazone; Stilbenes; Thiazolidinediones; Triglycerides | 2012 |
Higher levels of ATGL are associated with exercise-induced enhancement of lipolysis in rat epididymal adipocytes.
Topics: Acyltransferases; Adipocytes; Animals; Body Weight; Carrier Proteins; DNA; Epididymis; Gene Expression Regulation, Enzymologic; HeLa Cells; Humans; Insulin; Lipase; Lipolysis; Male; Organ Size; Perilipin-1; Phosphoproteins; Physical Conditioning, Animal; PPAR gamma; Protein Binding; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Sterol Esterase; Thiazolidinediones | 2012 |
Ursolic acid and rosiglitazone combination alleviates metabolic syndrome in high fat diet fed C57BL/6J mice.
Topics: Animals; Body Weight; Cyclooxygenase Inhibitors; Dietary Fats; Drug Therapy, Combination; Hypoglycemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triterpenes; Ursolic Acid | 2012 |
Plant extracts of winter savory, purple coneflower, buckwheat and black elder activate PPAR-γ in COS-1 cells but do not lower blood glucose in Db/db mice in vivo.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Chlorocebus aethiops; Cholesterol; COS Cells; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Echinacea; Fagopyrum; Female; Insulin; Mice; Plant Extracts; PPAR gamma; Rosiglitazone; Sambucus nigra; Satureja; Thiazolidinediones; Triglycerides | 2012 |
Rosiglitazone treatment does not decrease amyloid deposition in transplanted islets from transgenic mice expressing human islet amyloid polypeptide.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Graft Survival; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Time Factors | 2013 |
SUMO-1 regulates body weight and adipogenesis via PPARγ in male and female mice.
Topics: 3T3-L1 Cells; Adipogenesis; Adipose Tissue, White; Animals; Body Weight; Diet, High-Fat; Female; Male; Mice; Mice, Knockout; PPAR gamma; Rosiglitazone; SUMO-1 Protein; Thiazolidinediones | 2013 |
Protective effects of azelaic acid against high-fat diet-induced oxidative stress in liver, kidney and heart of C57BL/6J mice.
Topics: Animals; Antioxidants; Ascorbic Acid; Biomarkers; Blood Glucose; Body Weight; Dicarboxylic Acids; Diet, High-Fat; Eating; Erythrocytes; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Heart; Hypoglycemic Agents; Insulin; Kidney; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardium; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Triglycerides; Vitamin E | 2013 |
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Topics: Animals; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liver; Male; Oxazines; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Endothelin-1; Endothelins; Extracellular Matrix; Fenofibrate; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Oxygen; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tunica Media; Vascular Resistance; Vasodilator Agents | 2003 |
Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?
Topics: Animals; Appetite; Body Weight; Corticosterone; Dexamethasone; Female; Gene Expression; Glucocorticoids; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Organ Size; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Receptors, Glucocorticoid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Weight; Female; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Mutant Strains; Muscle, Skeletal; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; Endothelins; Fenofibrate; Fibrosis; Heart; Heart Ventricles; Hypertension; Myocardium; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Ventricular Remodeling | 2003 |
Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Diet; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glucose Tolerance Test; Heart; Hypoglycemic Agents; Insulin Resistance; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myocardium; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Body Weight; Cells, Cultured; Down-Regulation; Gene Expression Regulation; Giant Cells; Immunohistochemistry; In Situ Hybridization; Inflammation; Insulin Resistance; Lymphocytes; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Biological; Neutrophils; Obesity; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Up-Regulation | 2003 |
Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Administration Schedule; Drug Therapy, Combination; Insulin; Intubation, Gastrointestinal; Male; Pyrones; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Vanadates | 2003 |
Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Catheterization; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Fenofibrate; Hyperplasia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Ligands; Models, Cardiovascular; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Triglycerides; Tunica Intima | 2003 |
Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice.
Topics: Acyl Coenzyme A; Animals; Anticholesteremic Agents; Biological Transport; Blotting, Western; Body Weight; Cattle; Deoxyglucose; Diabetes Mellitus, Experimental; Glucose; Insulin; Insulin Resistance; Ligands; Ligases; Mice; Muscle, Skeletal; Muscles; Organic Chemicals; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors; Triglycerides; Tyrosine; Ubiquitin-Protein Ligases | 2004 |
Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model.
Topics: Animals; Body Weight; Capillary Permeability; Dietary Carbohydrates; Drug Interactions; Fructose; Hypoglycemic Agents; Male; Muscle, Skeletal; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A | 2004 |
Novel expression of resistin in rat testis: functional role and regulation by nutritional status and hormonal factors.
Topics: Adipocytes; Animal Nutritional Physiological Phenomena; Animals; Blotting, Southern; Body Weight; Cell Differentiation; Down-Regulation; Follicle Stimulating Hormone; Food Deprivation; Gene Expression Regulation; Gonadotropins; Hormones, Ectopic; Hypophysectomy; Immunohistochemistry; Insulin; Leydig Cells; Male; Mice; Mice, Obese; Polymerase Chain Reaction; PPAR gamma; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Resistin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Sertoli Cells; Testis; Thiazolidinediones; Time Factors; Vasodilator Agents | 2004 |
Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
Topics: Animals; Biomarkers; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin; Lipids; Macaca fascicularis; Male; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Characteristics; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Necrosis Factor-alpha | 2004 |
Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).
Topics: Absorptiometry, Photon; Adipocytes; Animals; Body Weight; Bone Density; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Hypoglycemic Agents; Osteoblasts; Ovariectomy; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Tibia; Triglycerides | 2004 |
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drinking; Drug Therapy, Combination; Drug Tolerance; Eating; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Pentanoic Acids; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors | 2005 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; Fructose; Hydrolases; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats.
Topics: Animals; beta-Adrenergic Receptor Kinases; Blood Glucose; Blood Pressure; Body Weight; Cell Membrane; Cyclic AMP-Dependent Protein Kinases; G-Protein-Coupled Receptor Kinase 4; GTP-Binding Protein alpha Subunits, Gs; Immunoprecipitation; Insulin; Insulin Resistance; Kidney Tubules, Proximal; Male; Obesity; Phosphorylation; Protein Serine-Threonine Kinases; Rats; Rats, Zucker; Receptors, Dopamine D1; Receptors, G-Protein-Coupled; Rosiglitazone; Thiazolidinediones | 2005 |
Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone.
Topics: Aging; Animals; Blood Glucose; Blood Pressure; Body Weight; Glucose Tolerance Test; Hypoglycemic Agents; Immunoblotting; Immunoenzyme Techniques; Kidney; Male; Natriuresis; Obesity; PPAR gamma; Proteinuria; Rats; Rats, Zucker; Receptors, Drug; Rosiglitazone; Sodium Chloride; Sodium Chloride Symporters; Solute Carrier Family 12, Member 3; Symporters; Telemetry; Thiazolidinediones; Tissue Distribution | 2005 |
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Cinnamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fenofibrate; Gene Expression Regulation, Enzymologic; Glucose; Homozygote; Humans; Hyperlipidemias; In Vitro Techniques; Insulin; Intercellular Signaling Peptides and Proteins; Kinetics; Lipid Metabolism; Liver; Male; Mice; Mice, Transgenic; Models, Chemical; PPAR alpha; PPAR gamma; Protein Binding; Protein Isoforms; Rats; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Triglycerides; Two-Hybrid System Techniques | 2005 |
[Rosiglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice].
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Female; Hypoglycemic Agents; Macrophages; Male; Mice; Mice, Knockout; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2005 |
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
Topics: Aldosterone; Animals; Biological Transport; Body Weight; Coloring Agents; Diabetes Mellitus, Type 2; Evans Blue; Gene Deletion; Genotype; Heterozygote; Hypoglycemic Agents; Immunohistochemistry; Integrases; Kidney; Kidney Tubules, Collecting; Mice; Mice, Knockout; Mice, Transgenic; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Nephrons; PPAR gamma; Promoter Regions, Genetic; Radioimmunoassay; Rosiglitazone; Sodium; Thiazolidinediones | 2005 |
Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Diet; DNA-Binding Proteins; Fatty Acids, Nonesterified; Female; Gemfibrozil; Hepatocyte Nuclear Factor 4; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Leptin; Liver; Liver X Receptors; Orphan Nuclear Receptors; PPAR alpha; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones.
Topics: Acridines; Animals; Benzyl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Male; Mice; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Fenofibrate; Gene Expression; Glucose Tolerance Test; Insulin; Intercellular Signaling Peptides and Proteins; Lipids; Male; Nicotinamide Phosphoribosyltransferase; PPAR alpha; PPAR gamma; Rats; Rats, Inbred OLETF; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Viscera | 2005 |
Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes.
Topics: Aged; Blood Pressure; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones | 2005 |
(+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Coronary Vessels; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Gene Expression; Hypoglycemic Agents; Kidney; Liver; Metabolic Syndrome; Obesity; Organ Size; Phenanthrenes; PPAR alpha; PPAR gamma; Random Allocation; Rats; Rats, Zucker; Risk Factors; Rosiglitazone; Selective Estrogen Receptor Modulators; Thiazolidinediones; Triglycerides | 2005 |
Rosiglitazone controls fatty acid cycling in human adipose tissue by means of glyceroneogenesis and glycerol phosphorylation.
Topics: Adipose Tissue; Adult; Body Weight; Fatty Acids; Female; Glycerol; Glycerol Kinase; Humans; Hypoglycemic Agents; Phosphorylation; Pyruvates; Rosiglitazone; Thiazolidinediones | 2006 |
Reactive oxygen species have a causal role in multiple forms of insulin resistance.
Topics: 3T3-L1 Cells; Animals; Antioxidants; Body Weight; Catalase; Glucose Tolerance Test; Insulin Resistance; Male; Metalloporphyrins; Mice; Mice, Obese; Obesity; Oxidation-Reduction; Reactive Oxygen Species; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Transgenes | 2006 |
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
Topics: 3T3-L1 Cells; Adipocytes; Anilides; Animals; Binding, Competitive; Body Weight; Dietary Carbohydrates; Dietary Fats; Disease Models, Animal; Glucose Tolerance Test; Hepatocytes; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.
Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Collagen; Insulin; Ligands; Liver; Lung; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Organ Size; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling | 2006 |
The long-term effects of rosiglitazone on serum lipid concentrations and body weight.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time; Triglycerides | 2006 |
Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blotting, Western; Body Weight; CD36 Antigens; Cell Movement; Chemokine CCL2; Colitis; Colon; Cytokines; Dendritic Cells; Dextran Sulfate; Fatty Acid-Binding Proteins; Gene Expression; Macrophages; Mice; Mice, Inbred Strains; Mice, Knockout; Neutrophils; Nitric Oxide Synthase Type II; PPAR gamma; Receptors, CCR2; Receptors, Chemokine; Receptors, Immunologic; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2007 |
Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Enalapril; Hypertension; Insulin; Insulin Resistance; Rats; Rats, Inbred SHR; Reference Values; Rosiglitazone; Thiazolidinediones; Vasoconstriction; Vasodilation | 2006 |
Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Blood Glucose; Body Weight; Cell Differentiation; Edema; Epithelial Sodium Channels; Erythrocyte Count; Fatty Acids; Glycine; Hemoglobins; Kidney; Mice; Mice, Inbred Strains; Oxazoles; PPAR alpha; PPAR gamma; RNA, Messenger; Rosiglitazone; Sodium; Sodium-Potassium-Exchanging ATPase; Thiazolidinediones; Transcriptional Activation | 2007 |
Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adiposity; Animals; Apoptosis; Body Weight; Dietary Fats; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Hypoglycemic Agents; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Leptin; Linoleic Acids, Conjugated; Lipid Metabolism; Lipoproteins, VLDL; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides | 2007 |
Comparison of mitochondrial and macrophage content between subcutaneous and visceral fat in db/db mice.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cell Count; Cell Shape; Cell Size; Chaperonin 60; Diabetes Mellitus; Disease Models, Animal; Intra-Abdominal Fat; Ion Channels; Macrophages; Male; Mice; Mitochondria; Mitochondrial Proteins; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Uncoupling Protein 1 | 2007 |
Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Body Weight; Carrier Proteins; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Intra-Abdominal Fat; Male; Mice; Perilipin-1; Phosphoproteins; Random Allocation; Rats; Rats, Inbred OLETF; Reverse Transcriptase Polymerase Chain Reaction; RNA; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Triglycerides | 2007 |
Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
The anti-diabetic effects of ethanol extract from two variants of Artemisia princeps Pampanini in C57BL/KsJ-db/db mice.
Topics: Animals; Artemisia; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet; Eating; Ethanol; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Liver; Liver Glycogen; Male; Mice; Mice, Inbred C57BL; Organ Size; Plant Extracts; Rosiglitazone; Solvents; Spectrophotometry, Ultraviolet; Thiazolidinediones | 2007 |
Exercise reverses high-fat diet-induced impairments on compartmentalization and activation of components of the insulin-signaling cascade in skeletal muscle.
Topics: Adipose Tissue; Animals; Body Weight; Cell Compartmentation; Diet, Atherogenic; Epididymis; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Male; Muscle, Skeletal; Phosphoproteins; Physical Conditioning, Animal; Protein Kinase C; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2007 |
Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Fatty Liver; Lipid Peroxidation; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Microscopy, Electron; Mitochondria, Liver; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tyrosine | 2007 |
Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B.
Topics: Adiposity; Animals; Body Weight; Creatine Kinase; Gene Deletion; Glucose; Homeostasis; Insulin; Mice; Mice, Knockout; Muscle, Skeletal; Organ Specificity; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides | 2007 |
Prolonged decrease of adipocyte size after rosiglitazone treatment in high- and low-fat-fed rats.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adiposity; Animals; Biopsy; Body Weight; Cell Size; Dietary Fats; Eating; Female; Hypoglycemic Agents; Insulin; Leptin; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Augmentation of nitric oxide is crucial for the time-dependent effects of rosiglitazone on blood pressure and baroreflex function in rats.
Topics: Administration, Oral; Animals; Arteries; Atropine Derivatives; Autonomic Nervous System; Baroreflex; Blood Glucose; Blood Pressure; Body Weight; Heart Rate; Insulin; Insulin Resistance; Linear Models; Lipids; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Propranolol; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sensitivity and Specificity; Thiazolidinediones; Time Factors | 2008 |
Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status.
Topics: Adipose Tissue; Adrenergic Fibers; Animals; Blood-Brain Barrier; Body Weight; Eating; Energy Metabolism; Hypothalamus; Injections, Intraventricular; Ion Channels; Male; Mice; Mitochondrial Proteins; Nerve Tissue Proteins; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thermogenesis; Thiazolidinediones; Thyroid Gland; Uncoupling Protein 1; Up-Regulation | 2008 |
The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glycated Hemoglobin; Heart Ventricles; Lipid Metabolism; Male; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Rosiglitazone; Streptozocin; Thiazolidinediones; Tyrosine | 2008 |
Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Body Weight; Dietary Fats; Female; Genotype; Glucose Tolerance Test; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Nitric Oxide Synthase Type II; Obesity; Phosphorylation; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2008 |
Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y.
Topics: Animals; Appetite Stimulants; Body Weight; Eating; Hyperphagia; Hypoglycemic Agents; Hypothalamus; Leptin; Male; Neuropeptide Y; Proteins; Rats; Rats, Wistar; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 1997 |
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Blood Pressure; Body Weight; Histocytochemistry; Hypoglycemic Agents; Immunohistochemistry; Islets of Langerhans; Kidney; Kidney Diseases; Male; Obesity; Pancreas; Pancreatic Diseases; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Systole; Thiazoles; Thiazolidinediones | 1998 |
A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Topics: Acyl-CoA Oxidase; Adipose Tissue; Animals; Blood Glucose; Body Weight; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression; Hypoglycemic Agents; Insulin; Ligands; Lipid Metabolism; Liver; Male; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Obesity; Organ Size; Oxidoreductases; Radioligand Assay; Rats; Rats, Wistar; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Transcriptional Activation; Triglycerides | 1998 |
Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution.
Topics: Animals; Body Weight; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Hemodilution; Hemodynamics; Hypoglycemic Agents; Insulin; Leptin; Male; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
Topics: Acyl-CoA Oxidase; Animals; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins C; Body Weight; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Male; Mice; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Oxidoreductases; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors; Transcription Factors; Triglycerides | 2000 |
Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Eating; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Carrier Proteins; Eating; Ion Channels; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Nicotinic Acids; Obesity; Proteins; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Weight Gain | 2000 |
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glucose; Body Weight; Cell Movement; Cells, Cultured; Chemokine CCL2; Chromans; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Endothelium, Vascular; Flavonoids; Fructose; Humans; Insulin; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Receptors, LDL; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2001 |
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Topics: Aging; Animals; Blood Glucose; Body Weight; Cell Death; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Organ Size; Pancreas; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Lipid Mobilization; Lipoproteins, VLDL; Liver; Male; Metabolic Clearance Rate; Muscle, Skeletal; Obesity; Oxidation-Reduction; Polyethylene Glycols; Postprandial Period; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2001 |
Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.
Topics: Animals; Body Weight; Carrier Proteins; Eating; Food Deprivation; Hyperphagia; Hypoglycemic Agents; Hypothalamus; Insulin Resistance; Ion Channels; Leptin; Male; Mitochondrial Proteins; Neuropeptide Y; Obesity; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Uncoupling Protein 3 | 2001 |
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
Topics: Adipocytes; Amino Acids; Animals; Binding Sites; Blood Glucose; Body Weight; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Fluorenes; Gene Expression Regulation; Genes, Reporter; Hypoglycemic Agents; Insulin Resistance; Leucine; Ligands; Male; Mice; Mice, Inbred Strains; Molecular Structure; Protein Binding; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tyrosine | 2001 |
Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Administration, Oral; Animals; Blood Glucose; Body Weight; Glucose; Glucose Clamp Technique; Glucose Transporter Type 1; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness | 2001 |
Thiazolidinediones influence plasma steroids of male obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Glucose; Hormones; Insulin; Male; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Cells, Cultured; Chromans; Disease Models, Animal; Gene Expression; Heart; Heterozygote; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; Myocardium; Organ Size; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Myocardial Reperfusion; Obesity; Organ Size; Perfusion; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2002 |
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blood Vessels; Body Weight; Cell Cycle Proteins; Cell Division; Collagen; DNA; Drug Administration Schedule; Endothelium, Vascular; In Vitro Techniques; Inflammation; Injections, Subcutaneous; Lipids; Male; NF-kappa B; Pioglitazone; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Renin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Vascular Cell Adhesion Molecule-1; Vasoconstrictor Agents; Vasodilator Agents | 2002 |
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |